Buscar
argenx SE
ARGXAñadir a la lista de seguimiento
852.500USD
-0.900-0.11%
Cierre 06/24, 16:00（ET）Cotizaciones retrasadas 15 min
52.76BCap. mercado
35.23P/E TTM
Más Datos de argenx SE Compañía
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Información de argenx SE
Símbolo de cotizaciónARGX
Nombre de la empresaargenx SE
Fecha de salida a bolsaJul 10, 2014
Director ejecutivovan Hauwermeiren (Tim)
Número de empleados1599
Tipo de seguridadDepository Receipt
Fin del año fiscalJul 10
DirecciónLaarderhoogtweg 25
CiudadAMSTERDAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal1101 EB
Teléfono31763030
Sitio Webhttps://www.argenx.com/
Símbolo de cotizaciónARGX
Fecha de salida a bolsaJul 10, 2014
Director ejecutivovan Hauwermeiren (Tim)
Ejecutivos de argenx SE
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Pamela M. (Pam) Klein
Dr. Pamela M. (Pam) Klein
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Dr. Luc Truyen
Dr. Luc Truyen
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Pamela M. (Pam) Klein
Dr. Pamela M. (Pam) Klein
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de argenx SE?
Los cinco principales accionistas de argenx SE son: Mr. Tim van Hauwermeiren
¿Cuántas instituciones poseen acciones de argenx SE (ARGX)?
A fecha de 2026Q1, 942 instituciones poseen acciones de argenx SE, con un valor de mercado combinado de aproximadamente 31.47M, lo que representa el 50.86% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2793210.00.
